$JANX

$17.26 +$0.57 (3.42%) Close

$JANX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 61.1M shares outstanding

Who owns JANX?

By type of holder

Institutions 99.4% Insiders 0.6% Everyone else 0.0%

Concentration Top 10 holders own 107.5%

Rajeev Shah 19.6% · Peter Kolchinsky 19.6%

Institutional ownership

99.4%

+2.0 pts vs last qtr

Institutional holders

197

+7 vs last qtr

Net shares bought

+1.2M

by institutions in Q2 2026

New / sold out

40 / 33

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Federated Hermes, Inc. +2.3M
Two Sigma Investments, LP +1.1M

Biggest sellers in Q2 2026

Janus Henderson Group PLC SOLD OUT −4.2M
Deep Track Capital, LP SOLD OUT −1.2M

Who is planning to sell?

Notices of proposed sale, last 12 months

$7.84M

10 notices from 5 people

Shares covered

514.1K

0.84% of the company

Arranged in advance

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

Andy Meyer Former affiliate $4.37M
Byron C Robinson Officer $2.12M

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2021–FY2025

+163.4%

+27.39% a year

Each share's claim on the business

−62.0%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $117M

over 5 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years46% 3–5 years10% 1–3 years27% Under 1 year16%

Quarterly turnover

19.6%

of institutional shares changed hands

Top 10 managers, median time held

4.8 years

Super Investors

Investment managers reporting JANX on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
RC Ra Capital Management, L.P. 13D · 19.9%	11.2M	18.30%	Unchanged	≤2021	1.5%
Shares held by quarter Peak holding11.2M (Q1'25) Change over 8 quarters+2.0M Share of the company18.300% Disclosed stake13D · 19.9% Ra Capital Management, L.P.'s full portfolio →
B BlackRock, Inc.	6.1M	10.03%	+701.4K (+12.9%)	≤2021	0.0%
Shares held by quarter Peak holding6.1M (Q2'26) Change over 8 quarters+3.7M Share of the company10.030% BlackRock, Inc.'s full portfolio →

Ra Capital Management, L.P.

13D · 19.9%

11.2M

% of company

18.30%

Change vs last qtr

Unchanged

Held since

≤2021

BlackRock, Inc.

6.1M

% of company

10.03%

Change vs last qtr

+701.4K (+12.9%)

Held since

≤2021

28 more super investors behind a free account

See every manager holding Janux Therapeutics, Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting JANX on Form N-PORT; together they hold 27.6% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
SS State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR Series Trust	$29.6M	1.9M	3.15%	0.28%	June 30, 2026
FH Federated Hermes MDT Small Cap Core Fund Federated Hermes MDT Series	$20.8M	1.4M	2.25%	0.93%	July 31, 2026

State Street(R) SPDR(R) S&P(R) Biotech ETF

SPDR Series Trust

Position value

$29.6M

% of company

3.15%

% of the fund

0.28%

As of

June 30, 2026

Federated Hermes MDT Small Cap Core Fund

Federated Hermes MDT Series

Position value

$20.8M

% of company

2.25%

% of the fund

0.93%

As of

July 31, 2026

23 more funds behind a free account

See every fund holding Janux Therapeutics, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
RS Rajeev Shah 5%+ holder 13D · 19.9%	12.0M	19.58%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company19.580% Disclosed stake13D · 19.9% View the 13D/G filing →
PK Peter Kolchinsky 5%+ holder 13D · 19.9%	12.0M	19.58%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company19.580% Disclosed stake13D · 19.9% View the 13D/G filing →

Rajeev Shah

5%+ holder13D · 19.9%

12.0M

% of company

19.58%

Change vs last qtr

—

Held since

—

Peter Kolchinsky

5%+ holder13D · 19.9%

12.0M

% of company

19.58%

Change vs last qtr

—

Held since

—

18 more holders behind a free account

See every insider and 5%+ holder of Janux Therapeutics, Inc..

Comments